News · 26 weeks147-46%
2025-12-282026-06-21
Mix8890d
- Insider42(48%)
- Other34(39%)
- SEC Filings8(9%)
- Earnings2(2%)
- Leadership1(1%)
- M&A1(1%)
Latest news
25 items- PRU.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal DiseaseCAPVAXIVE is the only Pneumococcal Conjugate Vaccine (PCV) specifically indicated and studied in the U.S. for use in this population CAPVAXIVE, when added to existing primary pediatric pneumococcal vaccination series, helps deliver additional protection by including serotypes not contained in approved primary pediatric PCV series Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) to include children and adolescents aged 2 through 17 years who have completed a primary pediatric pneumococcal vaccination series a
- PRStudy Reveals Dog Owners and Veterinarians See Challenges in Treating Allergic Skin Disease, Highlighting a Need for a Targeted Rapid Onset Treatment for Dogs of All AgesEfficacy and safety are top preferences when selecting antipruritic treatments, but dog owners and veterinarians want options that are easier to administer, more affordable and improve compliance Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced results from a new global survey of dog owners and veterinarians revealing challenges and pain points associated with diagnosing the underlying cause of allergic skin disease in dogs and its treatment. According to Pet Owner and Vet Perspectives on Canine Pruritus: A Global Survey, about one-third of canine patients seen by U.S. ve
- PRMerck Animal Health to Acquire TARGANTARGAN's innovative high-speed biodevice technology, including its gender identification product WingScan™, delivers enhanced poultry performance Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for an undisclosed purchase price. Merck Animal Health has invested in TARGAN since 2017 and has been one of the company's largest shareholders. The proposed acquisition is expected
- PRMerck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 StudyMerck (NYSE:MRK), known as MSD outside of the United States and Canada, and Gilead Sciences, Inc. (NASDAQ:GILD) today announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study investigating Gilead's Trodelvy® (sacituzumab govitecan-hziy) in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, compared to KEYTRUDA monotherapy in certain patients with previously untreated metastatic non-small cell lung cancer, whose tumors expressed PD-L1 (tumor proportion score [TPS] ≥50%). The decision is based on the recommendation from the external Data Monitoring Committee (eDMC) following their review of the data from the pre-specified final analysis of progression-free s
- PRApotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivityWESTON, Fla., June 3, 2026 /CNW/ - Apotex Corp. ("Apotex") today announced the U.S. launch of sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, both of which are eligible for 180‑day shared exclusivity. These launches expand Apotex's portfolio of treatment options for adults living with type 2 diabetes mellitus. Type 2 diabetes affects millions of adults in the United States, and treatment often requires long-term, reliable access to prescribed therapies. Sitagliptin tablets are AB rated (per FDA's Approved Drug Products with Therapeutic Equivalence Evaluations) to JANUVIA® (Merck) and are indicated as a
- INSIDERSEC Form 4 filed by Director Warden Kathy J4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Karsanbhai Surendralal Lanca4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Coe Mary Ellen4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Thulin Inge G4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Seidman Christine E4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Russo Patricia F4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Rothman Paul4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Mayo Stephen4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Lavizzo-Mourey Risa J4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Glocer Thomas H4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Craig Pamela J.4 - Merck & Co., Inc. (0000310158) (Issuer)
- INSIDERSEC Form 4 filed by Director Baker Douglas M Jr4 - Merck & Co., Inc. (0000310158) (Issuer)
- PRMerck to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceMerck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 11:20 a.m. ET. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to s
- NEWSModerna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual MeetingAt a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared to KEYTRUDA aloneIntismeran autogene in combination with KEYTRUDA demonstrated an encouraging trend toward overall survival in an exploratory analysis compared to KEYTRUDA alone (HR=0.471; [95% CI, 0.165-1.345]) CAMBRIDGE, MA AND RAHWAY, NJ / ACCESS Newswire / June 1, 2026 / Moderna, Inc. (NASDAQ:MRNA) and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced detailed results f
- SECSEC Form SD filed by Merck & Company Inc.SD - Merck & Co., Inc. (0000310158) (Filer)
- PRFDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)First Breakthrough Therapy designation for calderasib, supported by positive data from the Phase 1 KANDLELIT-001 trial Calderasib is an investigational, highly potent and specific next-generation KRAS G12C covalent inhibitor Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C-mutation and expr
- SECMerck & Company Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Merck & Co., Inc. (0000310158) (Filer)
- PRMerck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to CareKIRKLAND, QC, May 28, 2026 /CNW/ -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, congratulates the Government of Ontario for its recent regulatory amendments under the Pharmacy Act, 1991 to expand the scope of practice for pharmacy professionals. This important policy change marks a shift toward more connected, convenient care for Ontarians by increasing points of access. Starting in July 2026, pharmacists will be able to administer six additional publicly funded vaccines for eligible Ontarians, including tetanus, pertussis, diphtheria, pneumococcal, RSV
- PRMerck to Participate in the Jefferies Global Healthcare ConferenceMerck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 10:30 a.m. ET. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world
- PRMerck Announces Third-Quarter 2026 DividendMerck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the third quarter of 2026. Payment will be made on July 8, 2026, to shareholders of record at the close of business on June 15, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens
MRK FAQ
6 questionsWhat does Merck & Company Inc. do?
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected...Where does MRK stock trade?
Merck & Company Inc. (MRK) is listed on NYSE.What sector and industry is MRK in?
Merck & Company Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about MRK?
Merck & Company Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Neutral on 2026-05-06.What companies are similar to MRK?
Notable peers in the same industry include AZN (AstraZeneca PLC), NVS (Novartis AG), AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), PFE (Pfizer Inc.). Compare MRK side-by-side with any of them on Quantisnow.How can I track MRK on Quantisnow?
Quantisnow aggregates Merck & Company Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MRK to receive live email and push alerts on every new disclosure.